{
    "7BG.F": {
        "short_name": "BERGENBIO ASA",
        "long_name": "BerGenBio ASA",
        "summary": "BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bioavailable small molecule AXL inhibitor, which is in Phase II clinical development in two major cancer indications. The Phase II clinical trial program focuses on lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. In addition, it is developing tilvestamab, a function blocking antibody that is in Phase I clinical trial; and BGB601, a Phase I clinical trial antibody drug conjugate against human AXL that is linked to a cytotoxin. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was founded in 2007 and is headquartered in Bergen, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Bergen"
    },
    "7UM.F": {
        "short_name": "ULTIMOVACS AS  DK1",
        "long_name": "Ultimovacs ASA",
        "summary": "Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company engages in performing a clinical development program with clinical trials in Europe and the United States. Its lead product candidate is UV1, a peptide-based vaccine, which completed Phase I clinical trial that induces T cell response against the universal cancer antigen telomerase. The company was founded in 2011 and is headquartered in Oslo, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "8NN.F": {
        "short_name": "NORDIC NANOVECTOR NK 0,20",
        "long_name": "Nordic Nanovector ASA",
        "summary": "Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for haematological cancers. The company's lead product candidate is Betalutin, an antibody-radionuclide-conjugate, which has completed Phase I/IIa clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. Nordic Nanovector ASA has collaboration agreements with Paul Scherrer Institute; Areva Med; LegoChemBio; and Heidelberg Pharma. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was founded in 2009 and is headquartered in Oslo, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "AKBM.OL": {
        "short_name": "AKER BIOMARINE AS",
        "long_name": "Aker BioMarine AS",
        "summary": "Aker BioMarine AS, a biotechnology company, develops krill-derived ingredients and products for nutraceutical, aquaculture, and animal feed applications. The company provides krill oil products, including omega-3s, phospholipids, choline, and astaxanthin for the human market under the Superba brand. It also offers Qrill aqua product for aquaculture; and QRILL pet, a functional ingredient for pet food. Aker BioMarine AS has an agreement with Medical Food Solutions Research to develop pharmaceutical therapies for brain and eye health. The company is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Lysaker"
    },
    "B4V.F": {
        "short_name": "ARCTICZYMES TECH ASA NK 1",
        "long_name": "ArcticZymes Technologies ASA",
        "summary": "ArcticZymes Technologies ASA develops, manufactures, and markets immunomodulating beta-glucans and recombinant enzymes in Norway, Europe, Asia, Australia, Africa, and the Americas. It operates through two segments, Enzymes and Beta-Glucans. The company provides recombinant enzymes that are primarily derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics, and therapeutics. It offers shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing (NGS) processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of DNA from RNA samples; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; salt active nuclease for the removal of nucleic acids during manufacturing of vaccines, viruses, recombinant proteins, and other reagents; and ligases for joining DNA fragments. The company also provides immunomodulating beta-glucans products for the wound care, animal and consumer health, and adjuvants markets. It offers Woulgan wound gel; M-Glucan, a natural immune-stimulating product for fish and animal feed; and M-Gard, a natural immune-stimulating ingredients to enhance physical health. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Troms\u00c3\u00b8, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Troms\u00c3\u00b8"
    },
    "BGBIO.OL": {
        "short_name": "BERGENBIO ASA",
        "long_name": "BerGenBio ASA",
        "summary": "BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bioavailable small molecule AXL inhibitor, which is in Phase II clinical development in two major cancer indications. The Phase II clinical trial program focuses on lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. In addition, it is developing tilvestamab, a function blocking antibody that is in Phase I clinical trial; and BGB601, a Phase I clinical trial antibody drug conjugate against human AXL that is linked to a cytotoxin. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was founded in 2007 and is headquartered in Bergen, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Bergen"
    },
    "BRRGF": {
        "short_name": "BERGENBIO ASA",
        "long_name": "BerGenBio ASA",
        "summary": "BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bioavailable small molecule AXL inhibitor, which is in Phase II clinical development in two major cancer indications. The Phase II clinical trial program focuses on lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. In addition, it is developing tilvestamab, a function blocking antibody that is in Phase I clinical trial; and BGB601, a Phase I clinical trial antibody drug conjugate against human AXL that is linked to a cytotoxin. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was founded in 2007 and is headquartered in Bergen, Norway.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Norway",
        "city": "Bergen"
    },
    "C34.F": {
        "short_name": "CARASENT ASA  NK 1,332",
        "long_name": "Carasent ASA",
        "summary": "Carasent ASA provides cloud-based medical record services to the private and public health care industry in Nordic region. The company develops Webdoc, a cloud based EMR-system; and develops a digital platform for interactive health care to communicate through video, tele and health meetings, chat, and other online channels. It also provides training and consulting services. The company was formerly known as Apptix ASA and changed its name to Carasent ASA in May 2019. The company was founded in 1997 and is based in Oslo, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "CARA.OL": {
        "short_name": "CARASENT ASA",
        "long_name": "Carasent ASA",
        "summary": "Carasent ASA provides cloud-based medical record services to the private and public health care industry in Nordic region. The company develops Webdoc, a cloud based EMR-system; and develops a digital platform for interactive health care to communicate through video, tele and health meetings, chat, and other online channels. It also provides training and consulting services. The company was formerly known as Apptix ASA and changed its name to Carasent ASA in May 2019. The company was founded in 1997 and is based in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "CSAM.OL": {
        "short_name": "CSAM HEALTH GROUP",
        "long_name": "CSAM Health Group AS",
        "summary": "CSAM Health Group AS provides various ehealth solutions in Norway, Sweden, Denmark, and internationally. The company offers CSAM Arcidis, an integrated system for teleradiology; CSAM HelseMail for transfer of confidential patient data between healthcare organizations; CSAM Infobroker, a vendor-neutral telemedicine system for radiology that enables multiple clinicians to share resources and knowledge; CSAM S7, a platform for self-care and health counselling; CSAM Web Client, a web-based user interface and connectivity solution that allows users to access multiple CSAM applications and functions, including CSAM Cardio and CSAM Media; and CSAM XDS, a central archive for storing and managing various types of clinical patient data. It also provides CSAM CIMA, a mobile application for capturing, using, and sending medical media via mobile technology; CSAM Picsara, an image management solution that enables image capture, storing, and archiving in real time; CSAM Media, a web-based medical imaging solution; CSAM Medimaker for image management and workflow solution; and CSAM TRIS, a radiology information system. In addition, the company offers CSAM Partus, a maternity information system; CSAM Natus, a maternity care system; CSAM iPana Labor Information System, a web-based labour information system; and CSAM iPana Maternity, a cloud-based service platform that enables expectant mothers, hospitals, and maternity clinics to electronically collect, store, and share important medical information. Further, it provides CSAM AMIS, an emergency medical information system; CSAM Interactive Manchester Triage System (IMTS), an electronic tool for assessing and prioritizing patients based on the gold-standard Manchester triage scale; CSAM Paratus, an emergency response system in Sweden; CSAM Cytodose, an oncology management solution in the Nordics; and CSAM ProSang, an advanced laboratory information management system. The company was founded in 1999 and is headquartered in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "EXTX.OL": {
        "short_name": "EXACT THERAPEUTICS",
        "long_name": "EXACT Therapeutics AS",
        "summary": "EXACT Therapeutics AS, a clinical stage biotech company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology (chemotherapy and immunotherapy), infectious diseases, and neurological conditions. EXACT Therapeutics AS has a collaboration with GE Healthcare to develop an ultrasound probe to be used in studies using acoustic cluster therapy across various disease conditions. The company was founded in 2012 and is based in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "HBC.OL": {
        "short_name": "HOFSETH BIOCARE AS",
        "long_name": "Hofseth BioCare ASA",
        "summary": "Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for the human nutrition, and pet and feed markets in Norway. Its products include OmeGo salmon oil; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; and CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals. The company has a research agreement with Stanford University School of Medicine to investigate the gastro-intestinal-protective properties of HBC's salmon protein hydrolysate peptides in children and adults with GI tract disorders. The company was founded in 2000 and is headquartered in \u00c3\u0085lesund, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "\u00c3\u0085lesund"
    },
    "HBQ.F": {
        "short_name": "HOFSETH BIOCARE  NK 0,01",
        "long_name": "Hofseth BioCare ASA",
        "summary": "Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for the human nutrition, and pet and feed markets in Norway. Its products include OmeGo salmon oil; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; and CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals. The company has a research agreement with Stanford University School of Medicine to investigate the gastro-intestinal-protective properties of HBC's salmon protein hydrolysate peptides in children and adults with GI tract disorders. The company was founded in 2000 and is headquartered in \u00c3\u0085lesund, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "\u00c3\u0085lesund"
    },
    "HOFBF": {
        "short_name": "HOFSETH BIOCARE AS",
        "long_name": "Hofseth BioCare ASA",
        "summary": "Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for the human nutrition, and pet and feed markets in Norway. Its products include OmeGo salmon oil; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; and CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals. The company has a research agreement with Stanford University School of Medicine to investigate the gastro-intestinal-protective properties of HBC's salmon protein hydrolysate peptides in children and adults with GI tract disorders. The company was founded in 2000 and is headquartered in \u00c3\u0085lesund, Norway.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Norway",
        "city": "\u00c3\u0085lesund"
    },
    "INDCT.OL": {
        "short_name": "INDUCT AS",
        "long_name": "Induct Software AS",
        "summary": "Induct Software AS offers cloud-based innovation communities delivered as software as a service. Its platform that enables organizations to create, manage, track, and measure the innovation process from idea creation through to final implementation and impact reporting. The company serves private enterprises, governments, education and science networks, and healthcare industries. Induct Software AS has a strategic partnership with ICREA to expand its market penetration and presence in the United States, Europe, Africa, Indian Subcontinent, and GCC and CIS countries. The company was founded in 2007 and is headquartered in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "MD1.F": {
        "short_name": "MEDISTIM ASA  NK -,25",
        "long_name": "Medistim ASA",
        "summary": "Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was founded in 1984 and is headquartered in Oslo, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "MEDI.OL": {
        "short_name": "MEDISTIM ASA",
        "long_name": "Medistim ASA",
        "summary": "Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was founded in 1984 and is headquartered in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "N1A.F": {
        "short_name": "NAVAMEDIC ASA  NK 1",
        "long_name": "Navamedic ASA",
        "summary": "Navamedic ASA, a pharmaceutical company, markets and sells pharmaceuticals and other health care products in Northern European region. The company's product portfolio includes generic, branded, and patented pharmaceuticals, as well as medical devices, food supplements, cosmetics, and other health care products. It also distributes medical nutrition products for various metabolic disorders, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia type 1, MMA/PA, IVA, renal, MCT, low protein, single dose amino acids, glycogen storage disease, and ketogenic diet, as well as other products. In addition, the company sells consumer care products consisting of non-prescription drugs and health care products primarily through pharmacies and drugstores. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Oslo, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "NATTO.OL": {
        "short_name": "NATTOPHARMA ASA",
        "long_name": "NattoPharma ASA",
        "summary": "NattoPharma ASA engages in the research and development of vitamin K2 for applications in the marketplace for nutritional supplements and enriched foods. The company's flagship brand is MenaQ7, a vitamin K2 for bone and cardiovascular health. It also provides marketing and sales support services. The company has a partnership agreement with KD Nutra to create a cardiovascular-support ingredient that combines KD Nutra's KD-P\u00c3\u00bcR high concentrate omega-3s with the company's MenaQ7 PharmaPure MK-7; and a research partnership with the University of Maastricht to lead the exploration of K2 discovery and its role in improving human health. NattoPharma ASA was founded in 2004 and is headquartered in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "NAVA.OL": {
        "short_name": "NAVAMEDIC ASA",
        "long_name": "Navamedic ASA",
        "summary": "Navamedic ASA, a pharmaceutical company, markets and sells pharmaceuticals and other health care products in Northern European region. The company's product portfolio includes generic, branded, and patented pharmaceuticals, as well as medical devices, food supplements, cosmetics, and other health care products. It also distributes medical nutrition products for various metabolic disorders, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia type 1, MMA/PA, IVA, renal, MCT, low protein, single dose amino acids, glycogen storage disease, and ketogenic diet, as well as other products. In addition, the company sells consumer care products consisting of non-prescription drugs and health care products primarily through pharmacies and drugstores. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "OBSRV.OL": {
        "short_name": "OBSERVE MEDICAL",
        "long_name": "Observe Medical ASA",
        "summary": "Observe Medical ASA develops and markets medical technology products for patients, healthcare professionals, and hospitals in Europe and the United States. The company offers Sippi, a digital urine measuring system that automatically delivers data to electronic patient journal systems. It also develops Sippcoat, a technology that hampers the formation of biofilms in urine collection and drainage systems. The company was founded in 2009 and is headquartered in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "OM5A.F": {
        "short_name": "OBSERVE MEDICAL ASA -,26",
        "long_name": "Observe Medical ASA",
        "summary": "Observe Medical ASA develops and markets medical technology products for patients, healthcare professionals, and hospitals in Europe and the United States. The company offers Sippi, a digital urine measuring system that automatically delivers data to electronic patient journal systems. It also develops Sippcoat, a technology that hampers the formation of biofilms in urine collection and drainage systems. The company was founded in 2009 and is headquartered in Oslo, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "P99.MU": {
        "short_name": "PATIENTSKY GRP NK-,13736",
        "long_name": "PatientSky Group AS",
        "summary": "PatientSky Group AS provides cloud data platforms for health professionals and partners. It offers PatientSky 360 platform, a low-code development platform that allows vendors to interact intra-platform and reuse applications across customers, as well as platform-as-a-service partner program that provides a white labeling of the platform's modules and app. The company was founded in 2014 and is based in Oslo, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "PCIB.OL": {
        "short_name": "PCI BIOTECH HLDG",
        "long_name": "PCI Biotech Holding ASA",
        "summary": "PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's lead product candidate is Amphinex, a photosensitiser fimaporfin. Its PCI technology is applied to three distinct anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer, which in Phase Ib clinical study in bile duct cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination; and fimaNAc, a nucleic acid therapeutics delivery technology. The company has collaborative research programs with AstraZeneca, Bavarian Nordic, BioNTech, eTheRNA immunotherapies, IMV, and Phio Pharmaceuticals. PCI Biotech Holding ASA is headquartered in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "PHO.OL": {
        "short_name": "PHOTOCURE ASA",
        "long_name": "Photocure ASA",
        "summary": "Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to license partners, pharmaceutical wholesalers, and hospitals. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "PSKY.OL": {
        "short_name": "PATIENTSKY GROUP",
        "long_name": "PatientSky Group AS",
        "summary": "PatientSky Group AS provides cloud data platforms for health professionals and partners. It offers PatientSky 360 platform, a low-code development platform that allows vendors to interact intra-platform and reuse applications across customers, as well as platform-as-a-service partner program that provides a white labeling of the platform's modules and app. The company was founded in 2014 and is based in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "SOFTX.OL": {
        "short_name": "SOFTOX SOLUTIONS",
        "long_name": "SoftOx Solutions AS",
        "summary": "SoftOx Solutions AS, together with its subsidiaries, operates as a medtech company in Norway. Its SoftOx technology kills the microorganisms in biofilms by acting on various microbial components. The company engages in the development of SoftOx Wound Irrigation Solution that is under preclinical studies for the prevention and treatment of infections on breached or compromised skin, including acute wounds and skin lesions in patients with eczema; and SoftOx Biofilm Eradicator, which is in preclinical studies to treat biofilm infections in non-healing chronic wounds. The company was founded in 2012 and is headquartered in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "TA5.F": {
        "short_name": "TARGOVAX ASA  NK -,10",
        "long_name": "Targovax ASA",
        "summary": "Targovax ASA, a clinical stage immuno-oncology company, engages in the development of oncolytic viruses to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102 that is in Phase I/II clinical studies for the treatment of mesothelioma, melanoma, peritoneal disease, and prostate cancer. It also develops neoantigen cancer vaccines targeting tumors with oncogenic RAS\u00c2\u0096mutations. The company has collaboration agreements with Cancer Research Institute, Ludwig Cancer Research, and AstraZeneca to develop ONCOS-102 for peritoneal disease; Sotio to develop ONCOS-102 for prostate cancer; Valo Therapeutics to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Merck & Co., Inc. to evaluate ONCOS-102 in combination with KEYTRUDA in mesothelioma. Targovax ASA is based in Oslo, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "TRVX.OL": {
        "short_name": "TARGOVAX ASA",
        "long_name": "Targovax ASA",
        "summary": "Targovax ASA, a clinical stage immuno-oncology company, engages in the development of oncolytic viruses to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102 that is in Phase I/II clinical studies for the treatment of mesothelioma, melanoma, peritoneal disease, and prostate cancer. It also develops neoantigen cancer vaccines targeting tumors with oncogenic RAS\u00c2\u0096mutations. The company has collaboration agreements with Cancer Research Institute, Ludwig Cancer Research, and AstraZeneca to develop ONCOS-102 for peritoneal disease; Sotio to develop ONCOS-102 for prostate cancer; Valo Therapeutics to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Merck & Co., Inc. to evaluate ONCOS-102 in combination with KEYTRUDA in mesothelioma. Targovax ASA is based in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "VACC.OL": {
        "short_name": "VACCIBODY AS",
        "long_name": "Vaccibody AS",
        "summary": "Vaccibody AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of melanoma, lung, head and neck, renal, and bladder; and VB10.16, a therapeutic DNA vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. The company has clinical collaboration agreements with Roche and Nektar Therapeutics. Vaccibody AS was founded in 2007 and is based in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "VISTN.OL": {
        "short_name": "VISTIN PHARMA ASA",
        "long_name": "Vistin Pharma ASA",
        "summary": "Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients worldwide. It offers metformin active pharmaceutical ingredients and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was incorporated in 2015 and is headquartered in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "VP4.F": {
        "short_name": "VISTIN PHARMA ASA  NK 1",
        "long_name": "Vistin Pharma ASA",
        "summary": "Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients worldwide. It offers metformin active pharmaceutical ingredients and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was incorporated in 2015 and is headquartered in Oslo, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Oslo"
    }
}